Treatment of Pediatric SVT After a Fall
For a hemodynamically stable pediatric patient presenting with supraventricular tachycardia, adenosine is the definitive first-line pharmacologic treatment, with a 90-95% success rate in terminating the arrhythmia. 1, 2
Initial Assessment and Stabilization
Before any treatment, rapidly determine hemodynamic stability by assessing for:
- Signs of shock (poor perfusion, altered mental status, hypotension) 1, 3
- Respiratory compromise 3
- Chest pain or acute heart failure symptoms 3
While assessing, simultaneously establish IV or IO access, administer oxygen, and attach a cardiac monitor/defibrillator. 1, 3
Treatment Algorithm Based on Hemodynamic Status
If Hemodynamically UNSTABLE:
Proceed immediately to synchronized cardioversion at 0.5-1 J/kg without attempting vagal maneuvers or medications. 1, 2, 3 This achieves essentially 100% conversion in unstable patients. 3 Do not delay cardioversion for any pharmacologic intervention when the patient shows signs of cardiovascular compromise. 2, 3
If Hemodynamically STABLE:
Step 1: Vagal Maneuvers (unless this will unduly delay definitive treatment) 1
- In infants and young children: apply ice to the face without occluding the airway 1
- In older children: carotid sinus massage or Valsalva maneuvers (e.g., blowing through a narrow straw) 1
- Success rate approximately 27.7% 2
Step 2: Adenosine (First-Line Pharmacologic Agent)
Adenosine is the drug of choice with 90-95% effectiveness for terminating pediatric SVT. 1, 2, 4, 5
- Initial dose: 0.1 mg/kg (maximum 6 mg) rapid IV push 6
- Use the most proximal IV site possible 6
- Follow immediately with rapid saline flush 6
- If no response within 30 seconds, double the dose to 0.2 mg/kg (maximum 12 mg for second/subsequent doses) 6
- May be given intraosseously if IV access not achieved 6, 7
Critical safety requirements: 6
- Continuous ECG monitoring during administration 6
- Defibrillator must be immediately available 6
- Contraindicated in second- or third-degree AV block or sick sinus syndrome unless pacemaker placed 6
Expected side effects: Transient AV block, sinus bradycardia, ventricular extrasystoles, flushing, nausea, headache—all brief and self-limited. 4, 5
Why NOT the Other Options?
Amiodarone (Option A): Reserved only for refractory SVT after adenosine failure or for pulseless ventricular arrhythmias. 6, 8 It is NOT first-line for stable SVT. 2 Amiodarone carries significant risks including bradycardia, hypotension, and cardiovascular collapse in 71% of pediatric patients, and should only be used with cardiology consultation. 6, 8, 2
Cardioversion (Option C): Only indicated as first-line treatment in hemodynamically UNSTABLE patients. 1, 2, 3 In stable patients, it is reserved for adenosine failure. 2
Beta-blockers (Option D): NOT recommended for acute conversion of pediatric SVT. 2 Beta-blockers are limited to long-term prophylaxis in older children and adolescents, not acute management. 2
Common Pitfalls to Avoid
- Never delay cardioversion in unstable patients to attempt vagal maneuvers or medications. 2, 3
- Ensure rapid administration of adenosine via proximal IV with immediate saline flush—slow administration reduces efficacy. 6
- Watch for immediate reinitiation of SVT within seconds after successful conversion (occurs in 13-25% of cases). 4, 5 Consider longer-acting AV nodal blocking agents if this occurs. 9
- Avoid AV nodal blocking agents (including adenosine) if pre-excitation (Wolff-Parkinson-White) with atrial fibrillation is suspected, as this can precipitate ventricular fibrillation. 2, 3
Post-Conversion Management
After successful conversion, monitor continuously for recurrence and premature complexes that may trigger re-entry. 9 Arrange cardiology consultation for consideration of catheter ablation versus long-term pharmacologic prophylaxis. 2
Answer: B - Adenosine